In Practice: Clinical Insights
Choose from the two live presentation times below. Click the register button on the Microsoft Teams page to complete the form. A meeting link will be emailed to you upon registration.
Making Sense of Benzodiazepine Results: Clinical and Practical Implications of POCT vs. Definitive Testing
Date: April 30, 2026 | Time: 9:00am (CT) and 1:00pm (CT)
Please join us for an educational webinar on benzodiazepine results hosted by Dr. Chris Burke, Pharm.D., BCPS. Dr. Burke will discuss the clinical and practical implications of Point-of-Care Testing (POCT) vs Definitive Testing.
Webinar Objectives
By the end of this session, participants will be able to:
- Review key analytical limitations of POCT benzodiazepine immunoassays, including lorazepam, clonazepam metabolites, alprazolam metabolites, and emerging/non‑traditional benzodiazepines.
- Compare POCT results with definitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) findings and explain how discordant results may influence adherence assessment, risk evaluation, and clinical decision making.
- Identify clinical scenarios in which definitive LC-MS/MS benzodiazepine testing provides added value, such as suspected non prescribed use, polysubstance risk, or patient presentations inconsistent with POCT findings.
- Apply practical strategies for incorporating definitive LC-MS/MS testing into patient care, including when to consider additional testing based on clinical judgment or limitations of immunoassay performance.
This webinar will help healthcare providers gain a clearer understanding of why benzodiazepine test results can be misleading and how to interpret them more confidently in clinical practice. Ultimately, providers will learn practical strategies for selecting the right testing method and incorporating definitive testing into patient care decisions when results do not align with clinical presentation.
What Did My Patient Actually Take?
Potential causes of unexpected results in definitive testing
What Did My Patient Actually Take? An Overview of Cannabinoids and Semi-Synthetic Cannabinoids
Date: January 22, 2026
Length: 15 minutes
What Did My Patient Actually Take? Understanding Kratom Alkaloids in Clinical Practice
Date: November 20, 2025
Length: 15 minutes
Identifying the Use of Marijuana THC and Other Natural Cannabinoids
Date: December 15, 2023
Length: 20 minutes
What Did My Patient Actually Take? An Overview of Dextromethorphan/Levorphanol Results
Date: December 17, 2020
Length: 12 minutes
What Did My Patient Actually Take? An Overview of Benzodiazepine Results
Date: December 17, 2019
Length: 12 minutes
What Did My Patient Actually Take? A Review of Opioid Results Interpretation
Date: November 21, 2019
Length: 12 minutes
What Did My Patient Actually Take? An Overview of Marijuana Results
Date: October 24, 2019
Length: 8 minutes
What Did My Patient Actually Take? Unexpected Causes of Cocaine Results
Date: August 29, 2019
Length: 15 minutes
What Did My Patient Actually Take? An Overview of Amphetamine Results
Date: June 27, 2019
Length: 13 minutes
What Did My Patient Actually Take? An Overview of Methamphetamine Results
Date: July 17, 2019
Length: 13 minutes
Emerging Drug Trends
Stay up to date on the latest illicit & designer drug trends
Novel Psychoactive Substances 2025: A Year in Review
Date: March 19, 2026
Length: 25 minutes
2025 Mid-Year Update on Novel Psychoactive Substances (NPS) Trends
Date: August 21, 2025
Length: 25 minutes
Prevalent Adulterants Found in the Illicit Drug Supply
Date: April 30, 2025
Length: 15 minutes
Novel Psychoactive Substances 2024: A Year in Review
Date: February 18, 2025
Length: 15 minutes
New Nitazene Data – Ongoing Evaluation of an Emerging Threat
Date: June 25, 2024
Length: 15 minutes
Novel Psychoactive Substances: Newly Identified Threats Detected in the Second Half of 2022
Date: March 28, 2023
Length: 25 minutes
Novel Psychoactive Substances: What is Xylazine?
Date: January 24, 2023
Length: 15 minutes
Emerging Data on Novel Psychoactive Substances and Clinical Effects
Date: September 23, 2020
Length: 15 minutes
Clinical Considerations
Learn more about circumstances that may impact testing protocols and result interpretation
Opioid Use Disorder – Evaluating Risk of Return to Use
Date: October 28, 2025
Length: 15 minutes
New Additions to the Aegis Behavioral Health Testing Menu
Date: June 26, 2025
Length: 15 minutes
Responding to the Unexpected: Harm Reduction and Improved Outcomes
Date: October 29, 2024
Length: 15 minutes
Telemedicine Improvements After Epidemics Collide
Date: August 22, 2024
Length: 15 minutes
Managing Neonatal Abstinence Syndrome: Screening and Medication Monitoring
Date: May, 25, 2023
Length: 15 minutes
Behavioral Health: Why Monitor Patients for Medication Adherence
Date: August 31, 2022
Length: 15 minutes
Cases of Unusual Buprenorphine Concentrations in Urine Drug Tests: What Does This Mean and Clinical Implications?
Date: August 31, 2021
Length: 15 minutes
Interpretation of Buprenorphine Results: Considerations for Dosage Form and Specimen Type
Date: May 20, 2021
Length: 15 minutes
Evaluating Drug Interactions
Discusses the use of definitive testing for interacting substances and how the results can impact patient care
Spotlight on Potential Interactions Involving Behavioral Health & Substance Use Disorder Medications
Date: June 27, 2023
Length: 15 minutes
InterACT Rx Pharmacodynamic Insights: A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia
Date: October 25, 2022
Length: 20 minutes
Complexities of Risk Assessment: Opioids, Drug Interactions, & Designer Benzodiazepines
Date: September 28, 2022
Length: 17 minutes
InterACT Rx: A Look at Clinical Utility Through a Discussion of Interactions Found
Date: June 24, 2022
Length: 15 minutes
Enhanced DDI Identification and Patient Care with InterACT Rx
Date: March 15, 2019
Length: 27 minutes
